Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595468 | 0.83 | ACHE (0.42) | GPR119NAMPTCYP3A4ACHEBACE1 | |
| SCHEMBL6627397 | 0.78 | ACHE (0.39) | ACHEBACE1CCNE2CCNE1CDK2 | |
| SCHEMBL6035419 | 0.77 | ACHE (0.46) | NAMPTACHEBACE1 | |
| SCHEMBL6598152 | 0.75 | PIK3CA (0.33) | GPR119NAMPTGSK3B | |
| SCHEMBL6035089 | 0.71 | HRH3 (0.45) | NAMPTCYP3A4CCNE2CCNE1CDK2 | |
| SCHEMBL6604921 | 0.70 | CYP17A1 (0.32) | CCNE2CCNE1CDK2GSK3B | |
| SCHEMBL6604898 | 0.68 | CCNE2 (0.45) | NAMPTACHEBACE1CCNE2CCNE1 | |
| SCHEMBL4859748 | 0.67 | CYP17A1 (0.45) | NAMPTCYP3A4 | |
| SCHEMBL12018154 | 0.65 | CYP17A1 (0.48) | NAMPTCYP3A4 | |
| SCHEMBL30601022 | 0.65 | CYP17A1 (0.48) | NAMPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1406877-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004475-A1 | HETEROCYCLIC AMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |